Sepsis‑induced myopathy (SIM) is one of the leading causes of death in critically ill patients. SIM mainly involves the respiratory and skeletal muscles of patients, resulting in an increased risk of lung infection, aggravated respiratory failure, and prolonged mechanical ventilation and hospital stay. SIM is also an independent risk factor associated with increased mortality in critically ill patients. At present, no effective treatment for SIM has yet been established. However, mesenchymal stem cells (MSCs) have emerged as a promising therapeutic approach and have been utilized in the treatment of various clinical conditions. A significant body of basic and clinical research supports the efficacy of MSCs in managing sepsis and muscle‑related diseases. This literature review aims to explore the relationship between MSCs and sepsis, as well as their impact on skeletal muscle‑associated diseases. Additionally, the present review discusses the potential mechanisms and therapeutic benefits of MSCs in the context of SIM.
Keyphrases
- mesenchymal stem cells
- mechanical ventilation
- intensive care unit
- umbilical cord
- septic shock
- acute kidney injury
- respiratory failure
- skeletal muscle
- bone marrow
- acute respiratory distress syndrome
- end stage renal disease
- risk factors
- cell therapy
- healthcare
- extracorporeal membrane oxygenation
- newly diagnosed
- chronic kidney disease
- prognostic factors
- emergency department
- late onset
- adipose tissue
- case report
- metabolic syndrome
- electronic health record
- diabetic rats
- smoking cessation
- replacement therapy